FDA approves five generic versions of UCB's Keppra

ROCKVILLE, Md. The Food and Drug Administration has approved five new generic versions of the UCB's epilepsy drug Keppra, agency records show.

The FDA approved two versions of levetiracetam oral solution, from Cypress Pharmaceutical and Actavis Mid Atlantic, and three tablet formulations, from InvaGen Pharmaceuticals, Teva Pharmaceuticals and Wockhardt.

Keppra had sales of $1.36 billion in 2007, according to UCB financial data.